These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 24479749

  • 1. T-type Ca channel blockers in patients with chronic kidney disease in clinical practice.
    Abe M, Okada K, Soma M.
    Curr Hypertens Rev; 2013 Aug; 9(3):202-9. PubMed ID: 24479749
    [Abstract] [Full Text] [Related]

  • 2. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T.
    Circ Res; 2007 Feb 16; 100(3):342-53. PubMed ID: 17307972
    [Abstract] [Full Text] [Related]

  • 3. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
    Moore KH, Clemmer JS.
    Am J Physiol Renal Physiol; 2021 Oct 01; 321(4):F548-F557. PubMed ID: 34486399
    [Abstract] [Full Text] [Related]

  • 4. L-/N-type calcium channel blockers and proteinuria.
    Ando K.
    Curr Hypertens Rev; 2013 Aug 01; 9(3):210-8. PubMed ID: 24479751
    [Abstract] [Full Text] [Related]

  • 5. Renoprotective effects of the L-/T-type calcium channel blocker benidipine in patients with hypertension.
    Tomino Y.
    Curr Hypertens Rev; 2013 May 01; 9(2):108-14. PubMed ID: 23971692
    [Abstract] [Full Text] [Related]

  • 6. T-type Ca channel blockade as a determinant of kidney protection.
    Hayashi K, Homma K, Wakino S, Tokuyama H, Sugano N, Saruta T, Itoh H.
    Keio J Med; 2010 May 01; 59(3):84-95. PubMed ID: 20881449
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ, Li Y, Liu SM, Sun XG, Li M, Hao Y, Cui LQ, Wang AH.
    Ren Fail; 2016 Jul 01; 38(6):849-56. PubMed ID: 27055479
    [Abstract] [Full Text] [Related]

  • 9. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease.
    Omae K, Ogawa T, Nitta K.
    Heart Vessels; 2009 Jul 01; 24(4):301-7. PubMed ID: 19626404
    [Abstract] [Full Text] [Related]

  • 10. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL, Clase CM, Evans M, Lindholm B, Rotmans JI, Dekker FW, van Diepen M, Carrero JJ.
    Am J Kidney Dis; 2021 May 01; 77(5):719-729.e1. PubMed ID: 33246024
    [Abstract] [Full Text] [Related]

  • 11. Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis.
    Thamcharoen N, Susantitaphong P, Wongrakpanich S, Chongsathidkiet P, Tantrachoti P, Pitukweerakul S, Avihingsanon Y, Praditpornsilpa K, Jaber BL, Eiam-Ong S.
    Hypertens Res; 2015 Dec 01; 38(12):847-55. PubMed ID: 26134125
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of T-type selective calcium antagonist on renal microcirculation: studies in the isolated perfused hydronephrotic kidney.
    Ozawa Y, Hayashi K, Nagahama T, Fujiwara K, Saruta T.
    Hypertension; 2001 Sep 01; 38(3):343-7. PubMed ID: 11566902
    [Abstract] [Full Text] [Related]

  • 14. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
    Huang RS, Cheng YM, Zeng XX, Kim S, Fu P.
    Chin Med J (Engl); 2016 Mar 05; 129(5):562-9. PubMed ID: 26904991
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation.
    Hayashi K, Wakino S, Homma K, Sugano N, Saruta T.
    J Pharmacol Sci; 2005 Nov 05; 99(3):221-7. PubMed ID: 16293936
    [Abstract] [Full Text] [Related]

  • 17. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
    Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators.
    Kidney Int; 2007 Dec 05; 72(12):1543-9. PubMed ID: 17943080
    [Abstract] [Full Text] [Related]

  • 18. Potential risks of calcium channel blockers in chronic kidney disease.
    Griffin KA, Bidani AK.
    Curr Cardiol Rep; 2008 Nov 05; 10(6):448-55. PubMed ID: 18950553
    [Abstract] [Full Text] [Related]

  • 19. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR.
    Drugs; 2005 Nov 05; 65 Suppl 2():29-39. PubMed ID: 16398060
    [Abstract] [Full Text] [Related]

  • 20. Calcium channels blockers and progression of kidney disease.
    Ziakka S, Kaperonis N, Ferentinou E, Karakasis F, Ntatsis G, Kourvelou C, Papagalanis N.
    Ren Fail; 2007 Nov 05; 29(8):1003-12. PubMed ID: 18067048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.